In these cases, omissions or errors in the medication order may lead to dispensing from the wrong drug supply at the time orders are filled. Lastly, in the investigational study setting ...

Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in ...

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...

The global active pharmaceutical ingredients market size was worth USD 239.18 billion in 2024 and is expected to reach around USD 368.49 billion by 2033, with a noteworthy CAGR of 5.64% from 2023 to ...

An NIH report, ‘Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design’, highlighted that in June 2022 approximately 41% of pharmaceutical companies experienced supply ...